

IN THE CLAIMS

This listing of claims replaces all prior versions, and listings, in this application.

Claims 1-9 (canceled)

10. (currently amended) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of $184 \pm 3^{\circ}\text{C}$, comprising treating Clopidogrel base with dilute H_2SO_4 in one or more solvent(s), wherein at least one solvent is an alcohol, and subsequently isolating the crystalline form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of $184 \pm 3^{\circ}\text{C}$, from the solvent(s).

11. (currently amended) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of $184 \pm 3^{\circ}\text{C}$, comprising treating Clopidogrel base with concentrated H_2SO_4 in one or more solvent(s), wherein at least one solvent is an alcohol, and water and subsequently isolating the crystalline form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of $184 \pm 3^{\circ}\text{C}$, from the solvent(s).

12. (previously presented) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of $184 \pm 3^{\circ}\text{C}$, comprising dissolving/contacting Clopidogrel bisulfate in any form including crystalline forms II, III, IV, V, VI or any other crystalline forms or amorphous form or in the form of oil with one or more solvent(s) and subsequently isolating the crystalline form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of $184 \pm 3^{\circ}\text{C}$, from the solvent(s).

13. (previously presented) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of $184 \pm 3^{\circ}\text{C}$, comprising treating Clopidogrel bisulfate in any form including crystalline forms II, III, IV, V, VI or any other crystalline forms or amorphous form or in the form of oil is dissolved or contacted with one or more solvent(s) and water and subsequently isolating the crystalline form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of $184 \pm 3^{\circ}\text{C}$, from the solvent(s).

14. (previously presented) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of $184 \pm 3^{\circ}\text{C}$, comprising

- i. treating (S)-(+)-Clopidogrel camphor-sulfonate in a mixture of a solvent(s) and water with a base(s), to obtain Clopidogrel base wherein the solvent is selected from the group consisting of ethyl acetate, dichloromethane, dichloroethane, chloroform, and mixtures thereof;
- ii. treating the Clopidogrel base with dil. H_2SO_4 in a solvent(s); and
- iii. separating the crystals of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of $184 \pm 3^{\circ}\text{C}$, from the solvent(s).

15. (previously presented) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of $184 \pm 3^{\circ}\text{C}$, comprising

- i. treating (S)-(+)-Clopidogrel camphor-sulfonate in a mixture of a solvent(s) and water with a base, to obtain Clopidogrel base wherein the solvent is selected from the group consisting of ethyl acetate, dichloromethane, dichloroethane, chloroform, and mixtures thereof;
- ii. treating the Clopidogrel base with concentrated H_2SO_4 in a mixture of solvent(s) and water; and
- iii. separating the crystals of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of $184 \pm 3^{\circ}\text{C}$, from the solvent(s).

16. (previously presented) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of $184 \pm 3^{\circ}\text{C}$, comprising

- i. treating Clopidogrel base with dil. H_2SO_4 in solvent(s),
- ii. seeding with crystals of form-I, and
- iii. separating the crystals of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of $184 \pm 3^{\circ}\text{C}$, from the solvent(s).

17. (previously presented) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of $184 \pm 3^{\circ}\text{C}$, comprising

- i. treating Clopidogrel base with concentrated H_2SO_4 in solvent(s) and water,

- ii. seeding with crystals of form-I, and
- iii. separating the crystals of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of $184 \pm 3^{\circ}\text{C}$, from the solvent(s).

18. (previously presented) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of $184 \pm 3^{\circ}\text{C}$, comprising

- i. treating Clopidogrel camphor-sulfonate in a solvent(s) with a base, to obtain Clopidogrel base wherein the solvent is selected from the group consisting of ethyl acetate, dichloromethane, dichloroethane, chloroform, and [[or]] mixtures thereof;
- ii. treating the Clopidogrel base with dil. H_2SO_4 in a solvent(s);
- iii. seeding with crystals of form-I; and
- iv. separating the crystals of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of $184 \pm 3^{\circ}\text{C}$, from the solvent(s).

19. (previously presented) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of $184 \pm 3^{\circ}\text{C}$, comprising

- i. treating Clopidogrel camphor-sulfonate in one or more solvent(s) with a base, to obtain Clopidogrel base wherein the solvent is selected from the group consisting of ethyl acetate, dichloromethane, dichloroethane, chloroform, and mixtures thereof;
- ii. treating the Clopidogrel base with concentrated H_2SO_4 in a mixture of solvent(s) and water;
- iii. seeding with crystals of form-I; and
- iv. separating the crystals of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of $184 \pm 3^{\circ}\text{C}$, from the solvent(s).

20. (currently amended) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate claimed in claim 10, wherein the solvent is selected from the group consisting of $\text{C}_6\text{-C}_{12}$ alcohols which may be linear or branched, primary, secondary or tertiary

alcohols such as hexanol, 2-hexanol, 3-hexanol, isohexanol, heptanol, 2-heptanol, 3-heptanol, 4-heptanol, octanol, iso-octanol, decanol or mixtures thereof.

21. (previously presented) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate claimed in claim 10, wherein the base is selected from the group consisting of NaOH, KOH, LiOH, NaHCO₃, Na₂CO₃, and K₂CO₃.

Claims 22-24 (canceled)

25. (new) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate claimed in claim 10, wherein the solvent is selected from the group consisting of hexanol, 2-hexanol, 3-hexanol, isohexanol, heptanol, 2-heptanol, 3-heptanol, 4-heptanol, octanol, iso-octanol, decanol, and mixtures thereof.

26. (new) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate claimed in claim 11, wherein the solvent is selected from the group consisting of C₆-C₁₂ alcohols which may be linear or branched, primary, secondary or tertiary alcohols.

27. (new) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate claimed in claim 11, wherein the base is selected from the group consisting of NaOH, KOH, LiOH, NaHCO₃, Na₂CO₃, and K₂CO₃.

28. (new) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate claimed in claim 11, wherein the solvent is selected from the group consisting of hexanol, 2-hexanol, 3-hexanol, isohexanol, heptanol, 2-heptanol, 3-heptanol, 4-heptanol, octanol, iso-octanol, decanol, and mixtures thereof.